A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors

PURPOSE: Dovitinib is a receptor tyrosine kinase inhibitor of VEGFR1-3, PDGFR, FGFR1/3, c-KIT, FLT3 and topoisomerase 1 and 2. The drug response predictor (DRP) biomarker algorithm or DRP-Dovitinib is being developed as a companion diagnostic to dovitinib and was applied retrospectively. PATIENTS AN...

Descripción completa

Detalles Bibliográficos
Autores principales: Knudsen, Steen, Hansen, Anker, Foegh, Marie, Petersen, Steen, Mekonnen, Hana, Jia, Lin, Shah, Preeti, Martin, Victoria, Frykman, Gregory, Pili, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468037/
https://www.ncbi.nlm.nih.gov/pubmed/37647320
http://dx.doi.org/10.1371/journal.pone.0290681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468037/
https://www.ncbi.nlm.nih.gov/pubmed/37647320
http://dx.doi.org/10.1371/journal.pone.0290681

Ejemplares similares